Method for quantitatively detecting nitrosamine impurity in macassavir raw material medicine and intermediate TG9

By using high performance liquid chromatography-mass spectrometry combined with dynamic gradient elution and an acidic mobile phase, the problem of quantitative detection of nitrosamine impurities in mapasixavir raw material and intermediate TG9 was solved, achieving high sensitivity and stable detection results.

CN120870400APending Publication Date: 2025-10-31JOINCARE HAIBIN PHARM CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202511243929.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-02
Publication Date
2025-10-31

AI Technical Summary

Technical Problem

There is a lack of effective methods for quantitative detection of nitrosamine impurities TG801, TG901, and TG1001 in mapasixavir raw material and intermediate TG9.

Method used

High-performance liquid chromatography-mass spectrometry (HPLC-MS) was employed, combined with dynamic gradient elution and an acidic mobile phase. Formic acid acetonitrile solution was used to suppress protonation competition of nitrosamine impurities. By designing gradient elution programs for intermediates and active pharmaceutical ingredients respectively, baseline separation of TG801, TG901, and TG1001 was achieved, improving ionization efficiency and sensitivity.

Benefits of technology

A highly sensitive quantitative detection method for nitrosamine impurities in mapasixavir raw material and intermediate TG9 was achieved, with a limit of quantitation of 0.033 ng/g, ensuring the accuracy and stability of the detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120870400A_ABST
    Figure CN120870400A_ABST
Patent Text Reader

Abstract

The invention provides a method for quantitatively detecting a nitrosamine impurity in a macassavir raw material medicine and an intermediate TG9, and relates to the technical field of medicine detection, the method comprises the step of detecting the nitrosamine impurity in the macassavir raw material medicine or the intermediate TG9 sample by adopting a high performance liquid chromatography and mass spectrometry combined method, the mobile phase A is a formic acid solution, and the mobile phase B is a formic acid methanol solution; gradients, such as segmented gradients of the raw material medicines, are respectively designed for the intermediate and the raw material medicines through a dynamic gradient elution program, so that TG801, TG901 and TG1001 realize baseline separation; an acidic mobile phase is adopted, formic acid acetonitrile is added into the solution, protonation competition of nitrosamine impurities is inhibited, the ionization efficiency and stability are improved, the sensitivity is high, and the LOQ of the method is 0.033 ng / g. The technical problem that in the prior art, a method for quantitatively detecting three nitrosamine impurities in a macassavir raw material medicine and an intermediate TG9 does not exist is solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of drug detection technology, and in particular to a method for quantitatively detecting nitrosamine impurities in mapasxavir raw material and intermediate TG9. Background Technology

[0002] Mapaxixavir is a Class 1 innovative anti-influenza drug, a novel cap-dependent endonuclease inhibitor that effectively blocks viral replication and transmission. It features rapid onset of action, long-lasting viral inhibition, good tolerability, and is unaffected by food during oral administration. It can simultaneously and effectively inhibit both influenza A and B viruses. Its active pharmaceutical ingredient (API) is chemically named [[1'-[(11S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiazolin-11-yl]-1',2',4',6'-tetrahydro-4',6'-dioxospiro[cyclopropane-1,3'-[3H]pyridino[1,2-b]pyridazine]-5'-yl]oxy]methyl carbonate, with the following structure: Figure 1 As shown. The intermediate in the previous step of the drug substance synthesis is TG9, with the chemical name (S)-1'-(7,8-difluoro-6,11-dihydrodibenzo[b,e]thiazolin-11-yl)-5'-hydroxy-1',2'-dihydrospiro[cyclopropane-1,3'-[3H]pyrido[1,2-b]pyridazine]-4',6'-dione, and its structure is as follows. Figure 1 As shown. TG801, TG901, and TG1001 are nitrosamine impurities that may be introduced during the synthesis of the active pharmaceutical ingredient and intermediate TG9. Their structures are as follows. Figure 1 As shown, the active pharmaceutical ingredient (API), intermediate TG9, and nitrosamine impurities TG801, TG901, and TG1001 are all novel compounds, and there is currently no relevant literature on their detection. Therefore, developing a quantitative detection method for nitrosamine impurities TG801, TG901, and TG1001 in mapasixavir API and intermediate TG9 is an urgent problem to be solved.

[0003] In view of this, the present invention is hereby proposed. Summary of the Invention

[0004] One of the objectives of this invention is to provide a method for quantitatively detecting three nitrosamine impurities in mapasixavir raw material and intermediate TG9, in order to solve the technical problem that there is no method for quantitatively detecting three nitrosamine impurities in mapasixavir raw material and intermediate TG9 in the prior art.

[0005] In order to achieve the above-mentioned objectives of the present invention, the following technical solution is adopted: This invention provides a method for quantitatively detecting three nitrosamine impurities in mapasixavir raw material and intermediate TG9. The method includes using high performance liquid chromatography-mass spectrometry to detect nitrosamine impurities in mapasixavir raw material or intermediate TG9 samples; mobile phase A is formic acid solution and mobile phase B is formic acid methanol solution. The nitrosamine impurity includes at least one of TG801, TG901 or TG1001; When the test sample is mapasixavir active pharmaceutical ingredient, gradient elution includes: 0-12 min: 30±4% mobile phase A, 70±4% mobile phase B, 12-12.1 min: 30±4%-10% mobile phase A, 70±4%-90% mobile phase B. 12.1-16 min: 10% mobile phase A, 90% mobile phase B. 16-16.1 min: 10%-30±4% mobile phase A, 90%-70±4% mobile phase B. 16.1-19 min: 30±4% mobile phase A, 70±4% mobile phase B; When the test sample is intermediate TG9, gradient elution includes: 0-12 min: 30±4%-28% mobile phase A, 70±4%-72% mobile phase B. 12-12.5 min: 28%-5% mobile phase A, 72%-95% mobile phase B. 12.5-17.5 min: 5% mobile phase A, 95% mobile phase B. 17.5-17.6 min: 5±4%-30±4% mobile phase A, 95±4%-75±4% mobile phase B. 17.6-22 min: 30±4% mobile phase A, 70±4% mobile phase B.

[0006] Since TG901 and TG1001 have similar retention times, traditional isocratic elution or simple gradient elution cannot separate them. This invention designs gradients for intermediates and active pharmaceutical ingredients (APIs) separately using a dynamic gradient elution program, such as a segmented gradient for APIs, to achieve baseline separation of TG801, TG901, and TG1001. An acidic mobile phase is used, and formic acid acetonitrile is added to the solution to suppress protonation competition of nitrosamine impurities, improve ionization efficiency and stability, and has high sensitivity. The method LOQ is 0.033 ng / g.

[0007] In some specific embodiments, the volume concentration of the formic acid solution is 0.1%, and the volume concentration of the formic acid methanol solution is 0.1%.

[0008] In some specific embodiments, the high-performance liquid chromatography (HPLC) uses a C18 column with a length of 15 cm, a particle size of 3.5 μm, and an inner diameter of 4.6 mm; in some specific embodiments, the flow rate of the HPLC is 0.6 ± 0.04 ml / min; the injection volume is 10 ± 1 μL; in some specific embodiments, the column temperature of the HPLC is 25 ± 6 °C; in some specific embodiments, the injection plate temperature of the HPLC is 15 °C.

[0009] In some specific implementations, when the test sample is mapasixavir active pharmaceutical ingredient, gradient elution includes: 0-12 min: 30% mobile phase A, 70% mobile phase B. 12-12.1 min: 30%-10% mobile phase A, 70%-90% mobile phase B. 12.1-16 min: 10% mobile phase A, 90% mobile phase B. 16-16.1 min: 10%-30% mobile phase A, 90%-70% mobile phase B. 16.1-19 min: 30% mobile phase A, 70% mobile phase B; When the test sample is intermediate TG9, gradient elution includes: 0-12 min: 30%-28% mobile phase A, 70%-72% mobile phase B. 12-12.5 min: 28%-5% mobile phase A, 72%-95% mobile phase B. 12.5-17.5 min: 5% mobile phase A, 95% mobile phase B. 17.5-17.6 min: 5%-30±4% mobile phase A, 95%-75% mobile phase B. 17.6-22 min: 30% mobile phase A, 70% mobile phase B.

[0010] In some specific embodiments, the ion source of the mass spectrometer is an electrospray ionization source, and the scanning mode is negative ion mode and positive ion mode; the detection mode is multiple reaction monitoring mode. In some specific embodiments, the detection device of the mass spectrometer is a triple quadrupole liquid chromatography-mass spectrometry (LC-MS) system. In some specific embodiments, the nebulizing gas of the mass spectrometer is N2; the ionization temperature is 450°C; the curtain gas pressure is 35 psi; the collision gas pressure is 9 psi; the spray gas pressure is 50 psi; the auxiliary heating gas pressure is 50 psi; in negative ion mode, the ionization voltage of the mass spectrometer is -4500 V, the inlet voltage is -10 V, and the collision chamber outlet voltage is -10 V; in positive ion mode, the ionization voltage of the mass spectrometer is 5500 V, the inlet voltage is 10 V, and the collision chamber outlet voltage is 10 V.

[0011] In some specific embodiments, when the test sample is mapasixavir active pharmaceutical ingredient (API), the test sample solution is prepared by dissolving the mapasixavir API in diluent one. In some specific embodiments, the concentration of the mapasixavir API in the test sample solution is 10 mg / ml.

[0012] The active pharmaceutical ingredient (API) is alkaline. Under neutral or alkaline conditions, it readily competes with nitrosamine impurities for protons, leading to a decrease in the target impurity signal. In some specific embodiments, when the test sample is intermediate TG9, the test sample solution is prepared by dissolving intermediate TG9 in 5% formic acid acetonitrile. In some specific embodiments, the concentration of intermediate TG9 in the test sample solution is 10 mg / ml. In some specific embodiments, the diluent is prepared by dissolving intermediate TG9 (excluding TG801 and TG901) in 5% formic acid acetonitrile, with the concentration of intermediate TG9 being 0.95 mg / ml to 1.05 mg / ml, preferably 1 mg / ml. The addition of 5% formic acid acetonitrile to the solution further suppresses the protonation competition of nitrosamine impurities, improving ionization efficiency and stability.

[0013] In some specific embodiments, when the test sample is mapasixavir raw material, TG801, TG901, and TG1001 are used as reference standards, and the reference standard solution is prepared by dissolving TG801, TG901, and TG1001 in diluent two; in some specific embodiments, when the test sample is intermediate TG9, TG801 and TG901 are used as reference standards, and the reference standard solution is prepared by dissolving TG801 and TG901 in diluent one; in some specific embodiments, the concentrations of TG801, TG901, and TG1001 in the reference standard solution are independently 1.65 ng / ml to 5.0 ng / ml, preferably 3.3 ng / ml. In some specific embodiments, the diluent two is prepared by dissolving mapasixavir raw material (excluding TG801, TG901 and TG1001) and intermediate TG9 in 5% formic acid acetonitrile. The concentration of mapasixavir raw material is 9.5 mg / ml to 10.5 mg / ml, preferably 10 mg / ml, and the concentration of intermediate TG9 is 0.95 mg / ml to 1.05 mg / ml, preferably 1 mg / ml.

[0014] Both diluent 1 and diluent 2 use TG9 intermediate, which does not contain the target impurity, as a blank matrix to simulate the actual sample environment. Matrix matching eliminates the ion suppression effect and improves the peak shape, so that the accuracy of impurities meets the quantitative requirements of the method. At the same time, the use of 5% formic acid acetonitrile improves the solubility of the active pharmaceutical ingredient and intermediates, and the ionization of nitrosamine impurities is more stable, which can ensure that the correlation coefficient meets the method requirements (r>0.990).

[0015] This invention provides a method for the quantitative detection of three nitrosamine impurities in mapasixavir active pharmaceutical ingredient (API) and intermediate TG9. The method employs a dynamic gradient elution program with separately designed gradients for the intermediate and API, such as a segmented gradient for the API, to achieve baseline separation of TG801, TG901, and TG1001. An acidic mobile phase is used, with formic acid and acetonitrile added to the solution to suppress protonation competition from nitrosamine impurities, improving ionization efficiency and stability, resulting in high sensitivity. The method's LOQ is 0.033 ng / g. This method solves the technical problem of the lack of existing methods for the quantitative detection of three nitrosamine impurities in mapasixavir API and intermediate TG9. Attached Figure Description

[0016] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0017] Figure 1 The structural formulas of the mapasixavir active pharmaceutical ingredient, intermediate TG9, and nitrosamine impurities provided in this embodiment of the invention are as follows: A is the mapasixavir active pharmaceutical ingredient, B is the intermediate TG9, C is TG801, D is TG901, and E is TG1001. Figure 2 The linear spectrum of TG801 provided in Embodiment 1 of the present invention; Figure 3 The linear spectrum of TG901 provided in Embodiment 1 of the present invention; Figure 4 The typical chromatograms of the reference solution (STD) provided in Example 1 of the present invention are shown, wherein A is the chromatogram of TG801 and B is the chromatogram of TG901. Figure 5 The following are typical chromatograms of the blank solution provided in Example 1 of the present invention, wherein A is the chromatogram of TG801 and B is the chromatogram of TG901. Figure 6 The typical chromatograms of the spiked test solution provided in Example 1 of the present invention are shown, wherein A is the chromatogram of TG801 and B is the chromatogram of TG901. Figure 7 The typical chromatograms of the limit of quantitation solution provided in Example 1 of the present invention are shown, wherein A is the chromatogram of TG801 and B is the chromatogram of TG901. Figure 8 The linear spectrum of TG801 provided in Embodiment 2 of the present invention; Figure 9The linear spectrum of TG901 provided in Embodiment 2 of the present invention; Figure 10 The linear spectrum of TG1001 provided in Embodiment 2 of the present invention; Figure 11 The following are typical chromatograms of the reference solution (STD) provided in Example 2 of the present invention, wherein A is a chromatogram of TG1001, B is a chromatogram of TG801, and C is a chromatogram of TG901. Figure 12 The following are typical chromatograms of the blank solution provided in Example 2 of the present invention, wherein A is a chromatogram of TG1001, B is a chromatogram of TG801, and C is a chromatogram of TG901. Figure 13 The following are typical chromatograms of the spiked test solution provided in Example 2 of the present invention, wherein A is the chromatogram of TG1001, B is the chromatogram of TG801, and C is the chromatogram of TG901. Figure 14 The typical chromatograms of the limit of quantitation solution provided in Example 2 of the present invention are shown, wherein A is the chromatogram of TG1001, B is the chromatogram of TG801, and C is the chromatogram of TG901. Figure 15 The linear spectrum of TG901 provided in Comparative Example 1 of this invention; Figure 16 This is a typical chromatogram of the reference solution (SST) provided in Comparative Example 1 of the present invention; Figure 17 The following are typical chromatograms of the reference solution (SST) provided in Comparative Example 2 of the present invention, wherein A is a chromatogram of TG1001, B is a chromatogram of TG801, and C is a chromatogram of TG901. Detailed Implementation

[0018] The technical solution of the present invention will be clearly and completely described below with reference to the embodiments. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention. Unless otherwise specified, the materials in the embodiments are prepared according to existing methods or purchased directly from the market.

[0019] Example 1 A method for quantitatively detecting nitrosamine impurities in mapasixavir raw material and intermediate TG9. In this embodiment, the test sample is intermediate TG9 (batch number: CPo129342-02-07n08-01, source: Kairui Life Science Technology (Tianjin) Co., Ltd.).

[0020] 1.1 Specific methods 1.1.1 The method conditions are shown in Tables 1 to 4.

[0021] Table 1

[0022] Table 2 Mobile phase gradient

[0023] Table 3 Mass Spectrometry Conditions

[0024] Table 4 Ion pair parameters

[0025] 1.1.2 Solution Preparation 1.1.2.1 Mobile Phase Mobile phase A (0.1% formic acid solution): Take 2000 ml of water, add 2 ml of formic acid, mix well, and degas by sonication to obtain the mobile phase A.

[0026] Mobile phase B (0.1% formic acid in methanol): Take 2000 ml of methanol, add 2 ml of formic acid, mix well, and degas by sonication to obtain the mobile phase B.

[0027] 1.1.2.2 Diluent 5% Formic Acid Acetonitrile: Take 1000ml of acetonitrile, add 50ml of formic acid, mix well, and you have the product.

[0028] Diluent: Weigh 497.55 mg of the intermediate TG9 test sample (batch number: CPo129342-02-07n08-01, source: Kailaiying Life Science Technology (Tianjin) Co., Ltd.) which does not contain TG801 and TG901, place it in a 50 ml volumetric flask, dissolve and dilute to the mark with 5% formic acid acetonitrile, mix well, and the product is ready.

[0029] 1.1.2.3 Reference stock solution 1 Weigh appropriate amounts of each reference standard (TG801 and TG901 batch numbers: WS20230901 and WS20230913-1, respectively, source: Shenzhen Haibin Pharmaceutical Co., Ltd.), place them in a 5ml volumetric flask, add acetonitrile to dissolve and dilute to the mark, shake well, and prepare two parallel portions. The other portion is used as the stock solution of the verification reference standard. The concentrations are shown in Table 5.

[0030] Table 5

[0031] 1.1.2.4 Reference stock solution 2 Accurately measure an appropriate amount of each reference standard stock solution and place it in the same 10 ml volumetric flask. Dilute to the mark with 5% formic acid acetonitrile and shake well. Prepare the verification reference standard stock solutions in the same way, as shown in Table 6.

[0032] Table 6

[0033] 1.1.2.5 Reference stock solution 1 Accurately measure an appropriate amount of reference stock solution 2, place it in a 50 ml volumetric flask, dilute to the mark with 5% formic acid acetonitrile, and shake well. Prepare the verification reference stock solution 1 using the same method, as shown in Table 7.

[0034] Table 7

[0035] 1.1.2.6 Reference stock solution 2 Accurately measure an appropriate amount of reference stock solution 2, place it in a 50ml volumetric flask, dilute to the mark with 5% formic acid acetonitrile, and shake well to obtain the solution, as shown in Table 8.

[0036] Table 8

[0037] 1.1.2.7 Limit of Detection (LOD) solution, reference solution (STD1), verification reference solution (STD2), and linear solution Accurately measure appropriate amounts of each solution and place them in different volumetric flasks. Dilute to the mark with diluent, shake well, and the solution is obtained, as shown in Table 9.

[0038] Table 9

[0039] 1.1.2.8 Test solution Weigh 50.32 mg of this product and place it in a 5 ml volumetric flask. Dissolve and dilute to the mark with 5% formic acid acetonitrile, and shake well. Prepare two parallel portions. The other portion weighs 50.21 mg.

[0040] 1.2 Specific Verification Content 1.2.1 System Applicability and Specificity 1.2.1.1 Solution Preparation Blank solution: Prepared in the same way as the diluent under section 1.1.2.2.

[0041] Detection limit solution: Prepared in the same way as the detection limit solution in section 1.2.7.

[0042] Reference solution: Prepared in the same way as the reference solution and verification reference solution in section 1.1.2.7.

[0043] 100% Spiked Test Solution: Accurately weigh approximately 50 mg of this product and place it in a 5 ml volumetric flask. Dissolve the sample in 5% formic acid acetonitrile. Accurately add 165 μl of reference standard stock solution 1. Dilute to the mark with 5% formic acid acetonitrile and mix well. The sample weight in this test was 50.51 mg.

[0044] 1.2.1.2 Determination Method Take blank solution, reference solution, verification reference solution, detection limit solution and spiked test solution, and inject them according to Table 10.

[0045] Table 10

[0046] 1.2.1.3 Verification Results The results are shown in Tables 11-13. No TG901 peak was detected in the blank solution. The peak area of ​​the TG801 peak measured in the blank solution was smaller than that in the solution with the detection limit. For the reference solution, after six consecutive injections, the RSDs of the TG801 and TG901 peak areas were 4.08% and 19%, respectively, both less than 15%. The ratios of the TG801 and TG901 peak areas in the reference solution to the average peak areas of the previous six injections were 100.6% and 108.7%, respectively, both between 80% and 120%. The ratios of the TG801 and TG901 peak areas measured in each injection to the average peak areas of the previous six injections were 93.0% to 112%, both between 80% and 120%. The retention times of the TG801 and TG901 peaks in the reference solution and the spiked test solution were consistent. This method demonstrates good system applicability and specificity.

[0047] Table 11 System Applicability Test Results

[0048] Table 12 System Applicability Backflip Test Results

[0049] Table 13 Specificity Test Results

[0050] 1.2.2 Limit of Quantitation and Limit of Detection 1.2.2.1 Solution Preparation Limit of Quantification (LOQ) solution: Prepared in the same way as L1 under section 1.1.2.7.

[0051] Limit of Detection (LOD) solution: Prepared in the same way as LOD in section 1.1.2.7.

[0052] 1.2.2.2 Determination Method Take blank solution, limit of detection solution and limit of quantitation solution, and inject them according to Table 14.

[0053] Table 14

[0054] 1.2.2.3 Verification Results When the concentrations of TG801 and TG901 are both 0.33 ng / ml (equivalent to a sample content of 0.033 μg / g), and the solution is injected 6 times consecutively, the signal-to-noise ratio (S / N) of the TG801 and TG901 peaks are both greater than 10, the RSDs of the peak areas are 22% and 6.91% respectively, both less than 15%, and the RSDs of the retention times are 0.04% and 0.11% respectively, both less than 2%, which are within the limits of quantitation.

[0055] When the concentrations of TG801 and TG901 are both 0.15 μg / ml (equivalent to a sample content of 0.015 μg / g), the signal-to-noise ratio (S / N) of both TG801 and TG901 peaks is greater than 3, which is the detection limit. The results are presented in Tables 15 to 17.

[0056] Table 15 Results of quantitative peak area quantification

[0057] Table 16 Results of retention time at the limit of quantitation

[0058] Table 17. Signal-to-noise ratio results for limit of quantitation and limit of detection.

[0059] 1.2.3 Linearity and Range The linearity of concentration and peak area of ​​TG801 and TG901 in the range of 10% to 200% of the limit concentration was investigated.

[0060] 1.2.3.1 Solution preparation: Linear solutions L1~L5: Prepare L1~L5 in the same way as in section 1.1.2.7.

[0061] 1.2.3.2 Determination method: Take blank solution and each linear solution, and inject them according to Table 18 respectively.

[0062] Table 18

[0063] 1.2.3.3 Verification Results The results are shown in Table 19 and Figures 2-3As shown, TG801 and TG901 exhibited good linearity within the 10%–200% limit concentration range, with linear correlation coefficients r of 0.9970 and 0.9935, respectively, both greater than 0.990; the ratios of the absolute value of the intercept to the 100% response value on the Y-axis were 3.64% and 1.02%, respectively, both within 25%; and the sum of squared residuals were 1.59E+08 and 7.97E+08, respectively.

[0064] Table 19 Results of the linearity test

[0065] 1.2.4 Accuracy 1.2.4.1 Solution Preparation Test solution: Prepared as described in section 1.1.2.8. Prepare two parallel solutions, weighing 50.32 mg and 50.21 mg respectively.

[0066] 10% Spiked Test Solution (ACCL): Accurately weigh approximately 50 mg of this product and place it in a 5 ml volumetric flask. Dissolve the sample in 5% formic acid acetonitrile. Accurately add 165 μl of the reference standard stock solution 2. Dilute to the mark with 5% formic acid acetonitrile and mix well. Prepare three parallel aliquots with sample weights of 51.02 mg, 50.75 mg, and 50.19 mg.

[0067] 100% Spiked Test Solution (ACCM): One portion is to be used as the 100% spiked test solution under section 1.2.1.1, and the other two portions are to be prepared as under section 1.2.1.1. The sample weights are 50.51 mg, 51.34 mg, and 50.86 mg.

[0068] 152% Spiked Test Solution (ACCH): Accurately weigh approximately 50 mg of this product and place it in a 5 ml volumetric flask. Dissolve the solution in 5% formic acid acetonitrile. Accurately add 250 μl of the reference stock solution 1. Dilute to the mark with 5% formic acid acetonitrile and mix well. Prepare three parallel aliquots with sample weights of 51.10 mg, 51.41 mg, and 50.98 mg.

[0069] 1.2.4.2 Determination Method Take blank solution, test solution, and each spiked test solution, and inject them according to Table 20.

[0070] Table 20

[0071] 1.2.4.3 Verification Results The test results for the test samples are shown in Table 21, and the accuracy results are shown in Table 22. At the limit concentration levels of 10%, 100%, and 152%, the recoveries of TG801 and TG901 were 70.7%–104%, both within the range of 70%–125%; the RSDs of the recoveries of TG801 and TG901 and the overall recovery rate were 4.55%–13.44%, both less than 15%. This method has good accuracy.

[0072] Table 21 Test Results of the Samples

[0073] Table 22 Accuracy Results for Each Target

[0074] 1.2.5 Repeatability 1.2.1 Solution Preparation 100% spiked test solution (ACCM): Three of the solutions are shared with the 100% spiked test solution under section 1.2.4.1, and the other three solutions are prepared in parallel under section 1.2.1.1, with sample weights of 50.88 mg, 51.17 mg, and 50.57 mg.

[0075] 1.2.2 Determination Method Take blank solution and spiked test solution, and inject them according to Table 23.

[0076] Table 23

[0077] 1.2.2 Validation Results: The results are shown in Table 24. The RSDs of TG801 and TG901 content in the six spiked test samples were 4.98% and 9.96%, respectively, both less than 15%. The method has good repeatability.

[0078] Table 24 Results of Repeatability Tests

[0079] 1.2.6 Solution stability 1.2.6.1 Solution Preparation Reference solution: Used in conjunction with the reference solution described in section 1.2.1.1.

[0080] 100% spiked test solution: Used in conjunction with the spiked test solution under section 1.2.1.1.

[0081] 1.2.6.2 Determination method: The reference solution and the 100% spiked test solution were injected and analyzed at 15℃ at different times to investigate the stability of the reference solution and the spiked test solution at different time points.

[0082] 1.2.6.3 Verification Results The results are shown in Table 25. After being placed at 15℃ for 17.5 h, the ratio of the peak area measured by TG801 to the peak area measured at 0 h was 104%–116.6%, and the ratio of the peak area measured by TG901 to the peak area measured at 0 h was 104.9%–113.2%, both within the range of 80%–120%. The reference solution was stable at 15℃ for 17.5 hours.

[0083] The results are shown in Table 26. After being placed at 15℃ for 14.5 h, the ratio of the peak area measured by TG801 to the peak area measured at 0 h was 101.5%~104.9%, and the ratio of the peak area measured by TG901 to the peak area measured at 0 h was 93%~100%. The spiked test solution was stable at 15℃ for 14.5 hours.

[0084] Table 25 Results of stability study of reference solution

[0085] Table 26 Results of the stability study of the spiked test solution

[0086] 1.2.6 Method Durability 1.2.6.1 Solution Preparation Blank solution: Shared with the blank solution under section 1.2.1.1.

[0087] Reference solution: Used in conjunction with the reference solution and verification reference solution under section 1.2.1.1.

[0088] 100% spiked test solution: Used in conjunction with the spiked test solution under section 1.2.1.1.

[0089] 1.2.6.2 Measurement method: Blank solution, reference solution, verification reference solution and spiked test solution were injected under different conditions, chromatograms were recorded, and the RSD of TG801 and TG901 content in the spiked test solution under each condition was calculated.

[0090] 1.2.6.3 Verification Results The results are shown in Table 27. The spiked test solution was measured at flow rates of 0.58 ml / min, 0.60 ml / min, and 0.62 ml / min. The RSDs of TG801 and TG901 in the spiked test solution were 7.82% and 9.90%, respectively, both less than 15%. This method has good robustness.

[0091] Table 27 Durability Test Results

[0092] 1.3 Typical chromatograms of reference solution, blank solution, 100% spiked test solution, and limit of quantitation solution are as follows: Figures 4-7 As shown.

[0093] 1.4 Conclusion: Through system suitability and specificity, limit of quantitation and limit of detection, linearity and range, accuracy, repeatability, solution stability and method robustness studies, the results show that the established analytical method is suitable for the determination of TG801 and TG901 in TG9.

[0094] Example 2 A method for quantitatively detecting three nitrosamine impurities in mapasixavir raw material and intermediate TG9. In this embodiment, the test sample mapasixavir (batch number: E2404882, source: Shenzhen Haibin Pharmaceutical Co., Ltd.) is used.

[0095] 2.1 Specific methods 2.1.1 Method conditions: Chromatographic conditions are shown in Table 1, mobile phase gradients are shown in Table 28, mass spectrometry conditions are shown in Table 3, and ion pair parameters are shown in Table 29. These conditions can be adjusted according to the instrument and actual testing conditions. The peak cutting time is as follows: TripleQuad 6500+ instrument: 0-8.8 min for mass spectrometry, 8.8-10.5 min for waste liquid cutting, 10.5-19 min for mass spectrometry. API 5000 instrument: No peak cutting.

[0096] Table 28

[0097] Table 29

[0098] 2.1.2 Solution Preparation 2.1.2.1 Mobile Phase Mobile phase A (0.1% formic acid solution): Take 2000 ml of water, add 2 ml of formic acid, mix well, and degas by sonication to obtain the mobile phase A.

[0099] Mobile phase B (0.1% formic acid in methanol): Take 2000 ml of methanol, add 2 ml of formic acid, mix well, and degas by sonication to obtain the mobile phase B.

[0100] 2.1.2.2 Diluent 5% Formic Acid Acetonitrile Solution: Take 1000ml of acetonitrile, add 50ml of formic acid, mix well, and you have the solution.

[0101] Diluent 1: Take 200mg of intermediate TG9 (batch number: CPo129342-02-07n08-01, source: Kairui Life Science Technology (Tianjin) Co., Ltd.) without TG801 and TG901, accurately weigh it, place it in a 200ml volumetric flask, dissolve and dilute to the mark with 5% formic acid acetonitrile, mix well, and the product is ready.

[0102] Diluent 2: Take 2g of mapaxixavir (batch number: E2404882, source: Shenzhen Haibin Pharmaceutical Co., Ltd.) without TG801, TG901 and TG1001 and 200mg of intermediate TG9 (batch number: CPo129342-02-07n08-01, source: Kairui Life Science Technology (Tianjin) Co., Ltd.) without TG801 and TG901, accurately weigh them, place them in a 200ml volumetric flask, dissolve and dilute to the mark with 5% formic acid acetonitrile, mix well, and the product is ready.

[0103] 2.1.2.3 Reference stock solution 1 Weigh approximately 5 mg of each reference standard (batch numbers for TG801 and TG901 are WS20230901, WS20230913, and WS20230914, respectively; source: Shenzhen Haibin Pharmaceutical Co., Ltd.), place in a 5 ml volumetric flask, dissolve and dilute to the mark with acetonitrile, and shake well to obtain the solution, as shown in Table 30. Prepare two parallel solutions; the other solution is the verification reference standard stock solution 1.

[0104] Table 30

[0105] 2.1.2.4 Reference stock solution 2 Accurately measure an appropriate amount of each reference standard stock solution, place it in the same 10ml volumetric flask, dilute to the mark with 5% formic acid acetonitrile, and shake well to obtain the solution, as shown in Table 31.

[0106] Table 31

[0107] 2.1.2.5 Reference stock solution 1 Accurately measure an appropriate amount of the reference stock solution 2, place it in the same 10ml volumetric flask, dilute to the mark with 5% formic acid acetonitrile, shake well, and the result is shown in Table 32.

[0108] Table 32

[0109] 2.1.2.6 Standard solution (SST) Accurately measure 1165 μl of the reference standard stock solution and place it in a 5 ml volumetric flask. Dilute to the mark with diluent 2 and shake well. The concentration is shown in Table 33. Prepare two parallel solutions. One is the reference standard solution, and the other is the verification reference standard solution.

[0110] 2.1.2.7 Linear solutions and limit of detection (LOD) solutions Accurately measure an appropriate amount of the reference standard mother liquor 1, place it in different volumetric flasks, add diluent 2 to dilute to the mark, shake well, and the result is shown in Table 33.

[0111] Table 33

[0112] 2.1.2.8 Test solution Weigh approximately 50 mg of this product and place it in a 5 ml volumetric flask. Add diluent 1 to dissolve and dilute to the mark, then shake well to obtain the final product.

[0113] 2.1.2.9 Blank solution: Take diluent 2 from section 2.1.2.2 into a vial to obtain the blank solution.

[0114] 2.2 Specific Verification Content 2.2.1 System Applicability and Specificity 2.2.1.1 Solution Preparation Blank solution: Prepared in the same manner as described in section 2.1.2.9.

[0115] Detection limit solution: Prepared in the same way as the detection limit solution in section 2.1.2.7.

[0116] Reference solution: Prepare and verify the reference solution as described in section 2.1.2.6.

[0117] 100% spiked test solution: Accurately weigh 50 mg of this product, place it in a 5 ml volumetric flask, dissolve it in diluent 1, accurately add 165 μl of reference standard stock solution 1, dilute to the mark with diluent 1, and shake well. The sample weight is 50.86 mg.

[0118] 2.2.1.2 Determination method: Take blank solution, reference solution, verification reference solution, detection limit solution and spiked test solution, inject them according to Table 34, and record the chromatogram.

[0119] Table 34

[0120] 2.2.1.3 Verification Results The results are shown in Tables 35-37. The peak areas of TG801, TG901, and TG1001 in the blank solution were smaller than those in the limit-of-detection solution. After six consecutive injections of the reference solution, the RSD of each impurity peak area was 1.06%–3.24%, all less than 25%. The RSD of the peak areas of TG801, TG901, and TG1001 in the reference solution compared to the peak areas of the same impurities in the previous six injections was 1.6%–4.1%, all less than 25%. After no more than 12 injections, the reference solution was reinjected. The RSD of the peak areas of each impurity peak measured in the reinjected solution compared to the peak areas of the previous six injections was 1.14%–4.91%, all less than 25%. The retention times of each impurity peak in the reference solution and the spiked test solution should be consistent. This method demonstrates good system suitability and specificity.

[0121] Table 35 System Applicability Test Results

[0122] Table 36 System Suitability Backflip Test Results

[0123] Table 37 Specificity Test Results

[0124] 2.2.2 Limit of Quantitation and Limit of Detection 2.2.2.1 Solution Preparation Limit of Quantification (LOQ) solution: Prepared in the same manner as L1 / LOQ under section 1.1.2.7.

[0125] Limit of Detection (LOD) solution: Prepared in the same way as LOD in section 1.1.2.7.

[0126] 2.2.2.2 Determination Method Take blank solution, limit of detection solution and limit of quantitation solution, inject them according to Table 38, and record the chromatograms.

[0127] Table 38

[0128] 2.2.2.3 Verification Results The results are shown in Tables 39-41. The concentrations of TG801, TG901, and TG1001 were all 0.33 ng / ml (equivalent to a sample content of 0.033 μg / g). After six consecutive injections, the signal-to-noise ratio (S / N) of the TG801, TG901, and TG1001 peaks was greater than 10. The RSD of retention time was 0.01%–0.42%, all less than 2%, and the RSD of peak area was 3.07%–28.25%, all less than 30%, which were within the limits of quantitation. The concentrations of TG801, TG901, and TG1001 were all 0.15 ng / ml (equivalent to a sample content of 0.015 μg / g). After one injection, the signal-to-noise ratio (S / N) of the TG801, TG901, and TG1001 peaks was greater than 3, which were within the limits of detection.

[0129] Table 39 Results of quantitative peak area quantification

[0130] Table 40 Results of retention time at the limit of quantitation

[0131] Table 41. Signal-to-noise ratio results for limit of quantitation and limit of detection.

[0132] 2.2.3 Linearity and Range The linearity of concentration and peak area of ​​each impurity was examined within the limit concentration range of 10% to 200%.

[0133] 2.2.3.1 Solution Preparation Linear solutions L1 to L5: Prepared in the same way as L1 to L5 under section 2.1.2.7.

[0134] 2.2.3.2 Determination Method Take blank solution and each linear solution, inject them according to Table 42, and record the chromatograms.

[0135] Table 42

[0136] 2.2.3.3 Verification Results The results are shown in Table 43 and Figures 8-10 As shown, TG801, TG901, and TG1001 exhibit good linearity within the 10%–200% limit concentration range, with linear correlation coefficients r ranging from 0.9996 to 0.9999, all greater than 0.990. The ratio of the absolute value of the intercept to the 100% response value on the Y-axis ranges from 0.59% to 1.40%, all within 25%. The sums of squared residuals are 8.05E+07, 2.98E+07, and 1.28E+07, respectively.

[0137] Table 43 Results of Linearity Test

[0138] 2.2.4 Accuracy 2.2.4.1 Solution Preparation Test solution: Prepare two parallel solutions as described in section 2.1.2.8, weighing 50.54 mg and 50.12 mg respectively.

[0139] Reference stock solution 2: Accurately measure 1000 μl of reference stock solution 1, place it in a 10 ml volumetric flask, add 5% formic acid acetonitrile to dilute to the mark, shake well, and the solution is obtained (concentration is 10 ng / ml).

[0140] 10% Spiked Test Solution (ACCL): Accurately weigh approximately 50 mg of this product and place it in a 5 ml volumetric flask. Add diluent 1 to dissolve the sample. Accurately add 165 μl of the reference standard stock solution 2. Dilute to the mark with diluent 1 and mix well. Prepare three parallel aliquots, weighing 50.27 mg, 50.57 mg, and 50.20 mg respectively.

[0141] 100% spiked test solution (ACCM): One portion is used in the same way as the 100% spiked test solution under section 2.2.1.1, and the other two portions are prepared in the same way as under section 2.2.1.1, weighing 50.86 mg, 50.26 mg and 49.71 mg respectively.

[0142] 152% Spiked Test Solution (ACCH): Accurately weigh approximately 50 mg of this product and place it in a 5 ml volumetric flask. Add diluent 1 to dissolve the sample. Accurately add 250 μl of the reference stock solution from section 2.1.2.5. Dilute to the mark with diluent 1 and mix well. Prepare three parallel aliquots, weighing 50.33 mg, 50.57 mg, and 50.55 mg respectively.

[0143] 2.2.4.2 Determination Method Take blank solution, test solution, and each spiked test solution, inject them according to Table 44, and record the chromatograms.

[0144] Table 44

[0145] 2.2.4.3 Verification Results The results are shown in Tables 45 and 46. At the limit concentration levels of 10%, 100%, and 152%, the recoveries of TG801, TG901, and TG1001 ranged from 103.0% to 120.6%, all within the range of 70% to 125%. The RSDs of the recoveries of TG801, TG901, and TG1001, and the overall recovery rate, ranged from 1.05% to 57%, all less than 25%. The method has good accuracy.

[0146] Table 45 Test Results of the Samples

[0147] Not detected indicates that the detection limit is exceeded. Table 46 Accuracy Results for Each Target Object

[0148] 2.2.5 Precision 2.2.1 Solution Preparation 100% spiked test solution (ACCM): Three of the solutions are shared with the 100% spiked test solution under section 2.2.4.1, and the other three solutions are prepared in parallel as under section 2.2.1.1, with weights of 49.91 mg, 49.83 mg, and 50.37 mg.

[0149] 2.2.2 Determination method: Take blank solution and spiked test solution, inject them according to Table 47, and record the chromatograms.

[0150] Table 47

[0151] 2.2.2 Verification Results The results are shown in Table 48. The RSD of the contents of TG801, TG901 and TG1001 in the six spiked test samples were 3.00% to 4.82%, all of which were less than 25%.

[0152] Table 48 Results of Repeatability Tests

[0153] 2.2.6 Solution stability 2.2.6.1 Preparation of solutions: Reference solution: The same as the reference solution in section 1.2.1.1.

[0154] 2.2.6.2 Determination method: The reference solution was injected and analyzed at 15℃ at different times to investigate the stability of the reference solution at different time points.

[0155] 2.2.6.3 Verification Results The results are shown in Table 49. After being placed at 15°C for 14 hours, the ratio of the peak area measured by TG801, TG901, and TG1001 to the peak area measured at 0 hours was 99.6%–114.8%, all within the range of 80%–120%. The reference solution was stable at 15°C for 14 hours.

[0156] Table 49 Results of stability study of reference solution

[0157] 2.2.6 Method Durability 2.2.6.1 Solution Preparation Blank solution: Shared with the blank solution under section 2.2.1.1.

[0158] Reference solution: Used in conjunction with the reference solution and verification reference solution under section 2.2.1.1.

[0159] 100% spiked test solution: Used in conjunction with the spiked test solution under section 2.2.1.1.

[0160] 2.2.6.2 Determination method: Take blank solution, reference solution, verification reference solution and spiked test solution and inject them under different conditions, record the chromatogram, and calculate the RSD of each impurity content in the spiked test sample under each condition.

[0161] 2.2.6.3 Verification Results The results are shown in Table 50. Under column temperature conditions (25℃ and 27℃), two injections were performed on the same spiked sample solution. The RSDs of TG801, TG901, and TG1001 content in the spiked sample under each condition were 6.49%–7.15%, all less than 25%. This method exhibits good robustness only under the column temperature conditions (25℃ and 27℃).

[0162] Table 50 Durability Test Results

[0163] 2.3 Typical chromatograms: Typical chromatograms of standard solution (STD), blank solution, spiked test solution, and limit of quantitation solution are as follows: Figures 11-14 As shown.

[0164] 2.4 Conclusion: Through system suitability and specificity, limit of quantitation and limit of detection, linearity and range, accuracy, precision, solution stability and method robustness studies, the results show that the established analytical method is suitable for the determination of TG801, TG901 and TG1001 in mapasixavir raw material.

[0165] Comparative Example 1 Compared to Example 2, in this comparative example, the linear solution was not supplemented with a matrix or 5% formic acid. The linearity and peak shape of TG901 were examined, and the specific procedures were as follows.

[0166] 3.1 Specific methods 3.1.1 Method conditions: Chromatographic conditions are shown in Table 1, mobile phase gradient is shown in Table 51, mass spectrometry conditions are shown in Table 3, and ion pair parameters are shown in Table 4 for ion pair parameters named TG901-1 to TG901-4.

[0167] Table 51

[0168] 3.1.2 Solution Preparation 3.1.2.1 TG901 reference stock solution 1: Weigh 13.63 mg of TG901 (batch number: WS20230913, source: Shenzhen Haibin Pharmaceutical Co., Ltd.), place it in a 10 ml volumetric flask, add acetonitrile to dissolve and dilute to the mark, shake well, and the concentration is 1.266 mg / ml.

[0169] 3.1.2.2 TG901 reference stock solution 2: Take 179.0 μl of TG901 reference stock solution, put it into a 10 ml volumetric flask, add acetonitrile to dilute to the mark, shake well, and the concentration is 10.0 μg / ml.

[0170] 3.1.2.3 Reference solution 100 ng / ml: Accurately measure 100.0 μl of TG901 stock solution 2, place it in a 10 ml volumetric flask, dilute to the mark with acetonitrile, mix well, and the concentration is 100.0 ng / ml.

[0171] 50 ng / ml: Accurately measure 750 μl of 100 ng / ml TG901 reference solution, place it in a vial, add 750 μl of acetonitrile, mix well, and the concentration is 50.00 ng / ml.

[0172] 1 ng / ml: Accurately measure 100 μl of 100 ng / ml TG901 reference solution, place it in a 10 ml volumetric flask, dilute to the mark with acetonitrile, mix well, and the concentration is 1.000 ng / ml.

[0173] 3.1.2.4 Limit of Quantitation, Limit of Detection, and Preparation of Linear Solutions Accurately measure different volumes of the 100 ng / ml TG901 reference solution from section 3.1.2.3, place them in different volumetric flasks, dilute with acetonitrile to the corresponding volume, and mix well. See Table 52 for details.

[0174] Table 52

[0175] 3.1.2.5 Preparation of mobile phase Mobile phase A (0.1% formic acid solution): Take 1000 ml of water, add 1 ml of formic acid, mix well, and degas by sonication to obtain the mobile phase A.

[0176] Mobile phase B (0.1% formic acid in methanol): Take 500 ml of methanol, add 0.5 ml of formic acid, mix well, and degas by sonication to obtain the mobile phase B.

[0177] 3.2 Specific Confirmation Content 3.2.1 Linearity and Range The linearity of TG901 concentration and peak area in the range of 0.5 ng / ml to 100 ng / ml was investigated.

[0178] 3.2.1.1 Measurement Method Take blank solution and each linear solution, inject them according to Table 53, and record the chromatograms.

[0179] Table 53

[0180] 3.2.1.2 Results TG901 showed poor linearity in the range of 0.5 ng / ml-100 ng / ml, with a linear correlation coefficient r of 0.9815, which is less than 0.990; the linear spectrum is as follows. Figure 15 As shown.

[0181] 3.3 Typical chromatograms of standard solution (SST) are as follows: Figure 16 As shown.

[0182] 3.4 Conclusion: In this method, the TG901 peak is broadened, has a poor peak shape, and is unstable in ionization, resulting in poor linearity of TG901. This proves that the method for quantitative detection of three nitrosamine impurities (TG801, TG901, TG1001) in mapasixavir raw material and intermediate TG9 established without matrix or 5% formic acid has defects.

[0183] Comparative Example 2 Compared to Example 2, this comparative example uses a mobile phase gradient that is not sufficiently optimized.

[0184] 4.1 Specific methods 4.1.1 Method conditions: Chromatographic conditions are shown in Table 1, mobile phase gradient is shown in Table 54, mass spectrometry conditions are shown in Table 3, and ion pair parameters are shown in Table 29.

[0185] Table 54

[0186] 4.1.2 Solution Preparation 4.1.2.1 Mobile Phase Mobile phase A (0.1% formic acid solution): Take 2000 ml of water, add 2 ml of formic acid, mix well, and degas by sonication to obtain the mobile phase A.

[0187] Mobile phase B (0.1% formic acid in methanol): Take 2000 ml of methanol, add 2 ml of formic acid, mix well, and degas by sonication to obtain the mobile phase B.

[0188] 4.1.2.2 Diluent 5% Formic Acid Acetonitrile: Take 1000ml of acetonitrile, add 50ml of formic acid, mix well, and you have the product.

[0189] Diluent: Weigh 50.19 mg of intermediate TG9 (excluding TG801 and TG901), place it in a 50 ml volumetric flask, dissolve and dilute to the mark with 5% formic acid acetonitrile, mix well, and the product is ready.

[0190] 4.1.2.3 Reference Standard Stock Solution TG801 reference stock solution 1: Weigh 9.461 mg of TG801 reference standard, place it in a 5 ml volumetric flask, add acetonitrile to dissolve and dilute to the mark, shake well, and you will get the TG801 concentration of 1.838 mg / ml.

[0191] TG901 reference stock solution 1: Weigh 13.63 mg of TG901 reference standard, place it in a 10 ml volumetric flask, add acetonitrile to dissolve and dilute to the mark, shake well, and you will get the TG901 concentration of 1.266 mg / ml.

[0192] TG1001 reference stock solution 1: Weigh 0.26 mg of TG1001 reference standard, place it in a 5 ml volumetric flask, add acetonitrile to dissolve and dilute to the mark, shake well, and you will get the TG1001 concentration of 0.9806 mg / ml.

[0193] Reference stock solution 2: Accurately measure 154.4 μl of TG801 reference stock solution, 179.0 μl of TG901 reference stock solution, and 1102.0 μl of TG1001 reference stock solution, place them in the same 10 ml volumetric flask, dilute to the mark with 5% formic acid acetonitrile, and shake well to obtain (TG801 concentration is 10.01 μg / ml, TG901 concentration is 9.999 μg / ml, and TG1001 concentration is 10.00 μg / ml).

[0194] 4.1.2.4 Reference stock solution: Accurately measure 2100.0 μl of the reference stock solution, place it in a 10 ml volumetric flask, dilute to the mark with 5% formic acid acetonitrile, and shake well to obtain (TG801 concentration is 100.1 ng / ml, TG901 concentration is 99.99 ng / ml, and TG1001 concentration is 100.0 ng / ml).

[0195] 4.1.2.5 Limit of Detection (LOD) Solutions and Linear Solutions Accurately measure the reference standard stock solution according to Table 55, place it in different volumetric flasks, dilute with diluent to the mark, and shake well to obtain the final product.

[0196] Table 55

[0197] 4.1.2.6 Test solution: Weigh 50.85 mg of mapasixavir (batch number: WS20230901, source: Shenzhen Haibin Pharmaceutical Co., Ltd.), place it in a 5 ml volumetric flask, add diluent to dissolve and dilute to the mark, and shake well to obtain the test solution.

[0198] 4.1.2.7 Spiked test solution ACC-L (10%): Weigh 50.89 mg of this product (batch number: WS20230901, source: Shenzhen Haibin Pharmaceutical Co., Ltd.), place it in a 5 ml volumetric flask, add 500 μl of L3 solution, dissolve and dilute to the mark with diluent, shake well, and the product is ready.

[0199] ACC-M (100%): Weigh 50.43 mg of this product (batch number: WS20230901, source: Shenzhen Haibin Pharmaceutical Co., Ltd.), place it in a 5 ml volumetric flask, add 1165 μl of the reference standard stock solution, dissolve and dilute to the mark with diluent, shake well, and the product is ready.

[0200] ACC-H (150%): Weigh 102.33 mg of this product (batch number: WS20230901, source: Shenzhen Haibin Pharmaceutical Co., Ltd.), place it in a 10 ml volumetric flask, add 1500 μl of the reference standard stock solution, dissolve and dilute to the mark with diluent, and shake well to obtain the product.

[0201] 4.2 Specific Confirmation Content 4.2.1 Accuracy 4.2.1.1 Determination method: 5% formic acid acetonitrile, test solution, and each spiked test solution were injected according to Table 56, and the chromatograms were recorded.

[0202] Table 56

[0203] 4.2.1.2 Results The test samples and accuracy results are shown in Tables 57 and 58. At the limit concentration levels of 10%, 100%, and 150%, the recoveries of TG801 were 91%–107%, all within the range of 70%–125%; the recoveries of TG901 were 25%–108%; and the recoveries of TG1001 were 64%–77%.

[0204] Table 57 Test Results of the Samples

[0205] Where: ND indicates not detected (below the detection limit). Table 58 Accuracy Results

[0206] 4.3 Typical chromatograms of standard solution (SST) are as follows: Figure 17 As shown.

[0207] 4.4 Conclusion: In this method, the separation of TG901 and TG1001 is insufficient, and because the peak position of mapasixavir API is between the two, the main peak interferes with the impurity peaks, affecting the accuracy of both methods. It is necessary to adjust the mobile phase gradient to increase the separation of TG901 and TG1001, thereby weakening the influence of the API on the impurity peaks. This demonstrates that the established high-performance liquid chromatography-tandem mass spectrometry method for the quantitative detection of three nitrosamine impurities (TG801, TG901, and TG1001) in mapasixavir API and intermediate TG9 under these mobile phase conditions has defects.

[0208] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for quantitatively detecting three nitrosamine impurities in mapasixavir raw material and intermediate TG9, characterized in that, The method includes detecting nitrosamine impurities in mapasixavir raw material or intermediate TG9 sample using high performance liquid chromatography-mass spectrometry; mobile phase A is formic acid solution, and mobile phase B is formic acid methanol solution; the nitrosamine impurities include at least one of TG801, TG901 or TG1001. When the test sample is mapasixavir active pharmaceutical ingredient, gradient elution includes: 0-12 min: 30±4% mobile phase A, 70±4% mobile phase B, 12-12.1 min: 30±4%-10% mobile phase A, 70±4%-90% mobile phase B. 12.1-16 min: 10% mobile phase A, 90% mobile phase B. 16-16.1 min: 10%-30±4% mobile phase A, 90%-70±4% mobile phase B. 16.1-19 min: 30±4% mobile phase A, 70±4% mobile phase B; When the test sample is intermediate TG9, gradient elution includes: 0-12 min: 30±4%-28% mobile phase A, 70±4%-72% mobile phase B. 12-12.5 min: 28%-5% mobile phase A, 72%-95% mobile phase B. 12.5-17.5 min: 5% mobile phase A, 95% mobile phase B. 17.5-17.6 min: 5±4%-30±4% mobile phase A, 95±4%-75±4% mobile phase B. 17.6-22 min: 30±4% mobile phase A, 70±4% mobile phase B.

2. The method according to claim 1, characterized in that, The formic acid solution has a volume concentration of 0.1%, and the formic acid methanol solution has a volume concentration of 0.1%.

3. The method according to claim 1, characterized in that, The high-performance liquid chromatography uses a C18 column with a length of 15 cm, a particle size of 3.5 μm, and an inner diameter of 4.6 mm. Preferably, the flow rate of the high-performance liquid chromatography is 0.6 ± 0.04 ml / min; the injection volume is 10 ± 1 μL. Preferably, the column temperature of the high-performance liquid chromatography is 25±6℃; Preferably, the temperature of the injection plate of the high-performance liquid chromatograph is 15°C.

4. The method according to claim 1, characterized in that, When the test sample is mapasixavir active pharmaceutical ingredient, gradient elution includes: 0-12 min: 30% mobile phase A, 70% mobile phase B. 12-12.1 min: 30%-10% mobile phase A, 70%-90% mobile phase B. 12.1-16 min: 10% mobile phase A, 90% mobile phase B. 16-16.1 min: 10%-30% mobile phase A, 90%-70% mobile phase B. 16.1-19 min: 30% mobile phase A, 70% mobile phase B; When the test sample is intermediate TG9, gradient elution includes: 0-12 min: 30%-28% mobile phase A, 70%-72% mobile phase B. 12-12.5 min: 28%-5% mobile phase A, 72%-95% mobile phase B. 12.5-17.5 min: 5% mobile phase A, 95% mobile phase B. 17.5-17.6 min: 5%-30±4% mobile phase A, 95%-75% mobile phase B. 17.6-22 min: 30% mobile phase A, 70% mobile phase B.

5. The method according to claim 1, characterized in that, The ion source for the mass spectrometer is an electrospray ion source, and the scanning mode is a negative ion mode and a positive ion mode; the detection mode is a multiple reaction monitoring mode.

6. The method according to claim 1, characterized in that, The mass spectrometer uses N2 as the nebulizing gas; the ionization temperature is 450°C; the curtain gas pressure is 35 psi; the collision gas pressure is 9 psi; the spray gas pressure is 50 psi; and the auxiliary heating gas pressure is 50 psi. In negative ion mode, the ionization voltage of the mass spectrometer is -4500V, the inlet voltage is -10V, and the collision chamber outlet voltage is -10V. In positive ion mode, the ionization voltage of the mass spectrometer is 5500V, the inlet voltage is 10V, and the collision chamber outlet voltage is 10V.

7. The method according to claim 1, characterized in that, The mass spectrometer is a triple quadrupole liquid chromatography-mass spectrometry (LC-MS) system.

8. The method according to any one of claims 1 to 7, characterized in that, When the test sample is mapasixavir active pharmaceutical ingredient, the test sample solution is prepared by dissolving mapasixavir active pharmaceutical ingredient in diluent 1; When the test sample is intermediate TG9, the test sample solution is prepared by dissolving intermediate TG9 in 5% formic acid acetonitrile; Preferably, the concentration of mapasixavir raw material or intermediate TG9 in the test solution is 10 mg / ml.

9. The method according to claim 8, characterized in that, When the test sample is mapasixavir raw material, TG801, TG901 and TG1001 are used as reference standards. The reference standard solution is prepared by dissolving TG801, TG901 and TG1001 in diluent 2. When the test sample is intermediate TG9, TG801 and TG901 are used as reference standards. The reference standard solution is prepared by dissolving TG801 and TG901 in diluent 1. Preferably, the concentrations of TG801, TG901, and TG1001 in the reference solution are independently 1.65 ng / ml to 5.0 ng / ml, and more preferably 3.3 ng / ml.

10. The method according to claim 9, characterized in that, The diluent is prepared by dissolving intermediate TG9, which does not contain TG801 and TG901, in 5% formic acid acetonitrile. The concentration of intermediate TG9 is 0.95 mg / ml to 1.05 mg / ml, preferably 1 mg / ml. The second diluent is prepared by dissolving mapasixavir raw material (excluding TG801, TG901 and TG1001) and intermediate TG9 in 5% formic acid acetonitrile. The concentration of mapasixavir raw material is 9.5 mg / ml to 10.5 mg / ml, preferably 10 mg / ml, and the concentration of intermediate TG9 is 0.95 mg / ml to 1.05 mg / ml, preferably 1 mg / ml.

Citation Information

Cited By

  • Method for quantitatively detecting genotoxic impurities in acarbose bulk drug by high performance liquid chromatography-tandem mass spectrometry

    CN122238549A